Free Trial

Affimed (AFMD) Stock Forecast & Price Target

$5.12
-0.09 (-1.73%)
(As of 07/24/2024 ET)

Affimed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 6 Wall Street analysts who have issued ratings for Affimed in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for AFMD.

Consensus Price Target

$41.67
713.80% Upside
High Forecast$70.00
Average Forecast$41.67
Low Forecast$10.00

According to the 6 analysts' twelve-month price targets for Affimed, the average price target is $41.67. The highest price target for AFMD is $70.00, while the lowest price target for AFMD is $10.00. The average price target represents a forecasted upside of 713.80% from the current price of $5.12.

TypeCurrent Forecast
7/26/23 to 7/25/24
1 Month Ago
6/26/23 to 6/25/24
3 Months Ago
4/27/23 to 4/26/24
1 Year Ago
7/26/22 to 7/26/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$41.67$41.67$45.00$55.00
Forecasted Upside713.80% Upside599.64% Upside740.42% Upside336.43% Upside
Get Affimed Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

AFMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AFMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Affimed Stock vs. The Competition

TypeAffimedMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside713.80% Upside3,257.63% Upside10.62% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/13/2024Laidlaw
5 of 5 stars
 Boost TargetBuy$15.00 ➝ $25.00+252.11%
6/13/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00+45.77%
4/1/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight
4/1/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$30.00 ➝ $25.00+357.87%
8/11/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$80.00 ➝ $60.00+1,003.95%
8/8/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$60.00+971.43%
3/24/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$20.00 ➝ $10.00+42.51%
12/12/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$100.00 ➝ $60.00+194.12%
12/12/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$70.00 ➝ $60.00+194.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:46 AM ET.

AFMD Forecast - Frequently Asked Questions

What is Affimed's forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Affimed is $41.67, with a high forecast of $70.00 and a low forecast of $10.00.

Should I buy or sell Affimed stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AFMD shares.

Does Affimed's stock price have much upside?

According to analysts, Affimed's stock has a predicted upside of 599.64% based on their 12-month stock forecasts.

What analysts cover Affimed?

Affimed has been rated by research analysts at HC Wainwright, and Laidlaw in the past 90 days.

Do Wall Street analysts like Affimed more than its competitors?

Analysts like Affimed more than other "medical" companies. The consensus rating for Affimed is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AFMD compares to other companies.


This page (NASDAQ:AFMD) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners